Clinical Trial Update: Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating flexible dosing of brexpiprazole for agitation in Alzheimer's disease; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation in Alzheimer Disease
• Alzheimer Disease

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Agitation Associated With, Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-07-07